Kalp Yetersizliklerinde Sezaryen Anestezisi
Özet
Gebelikte plazma hacmi ve kalp debisindeki fizyolojik artışlar altta yatan kalp rahatsızlıklarını tetikleyerek maternal ve fetal morbidite ile mortaliteyi artıran kalp yetersizliğine (KY) yol açabilmektedir. Gebelikte KY sıklıkla peripartum kardiyomiyopati, kapak hastalıkları, doğumsal ve iskemik kalp hastalıklarından kaynaklanmaktadır. Kalp hastalığı olan gebelerin kardiyovasküler risklerinin değerlendirilmesinde NYHA, CARPREG I, CARPREG II, ZAHARA ve DSÖ risk sınıflandırma modelleri kullanılmakta; maternal komplikasyonları tahmin etmede DSÖ modelinin en iyi performansı gösterdiği belirtilmektedir. En yüksek riskli gebelerde multidisipliner doğum planlaması ile acil durum ihtiyacını önleyen planlı sezaryen doğum tercih edilmektedir. Anestezi yönetiminde nöroaksiyel anestezi (spinal, epidural veya kombine spinal-epidural [KSE]) genel anestezinin ve pozitif basınçlı ventilasyonun risklerinden koruduğu için öne çıkarken, hemodinamik kademeli başlangıç ve simetrik blok sağlayan sıralı KSE tekniği sıklıkla uygulanmaktadır. Antikoagülan kullanımı nedeniyle epidural hematom riski olan, pulmoner ödem gelişen veya hemodinamik olarak stabil olmayan hastalarda ise genel anestezi zorunlu hale gelmekte; entübasyona bağlı kardiyovasküler yanıtı baskılamak için remifentanil premedikasyonu ve etomidat indüksiyonu tercih edilebilmektedir. İntra-arteriyel kateter, santral venöz kateter ve TEE gibi invaziv izlemler hayati önem taşımaktadır. Doğum sonrası dönemde ise klinik tabloları ayırt etmede BNP düzeylerinin (<100 pg/ml) yüksek negatif prediktif değeri bulunmakta, kardiyolog, kadın doğum uzmanı, perinatolog ve anestezi uzmanından oluşan multidisipliner ekibin takibi anne ölümlerini azaltmada temel bir husus oluşturmaktadır.
Referanslar
Hunt SA, Baker DW, Chin MH, et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation 2001; 104: 2996-3007
Aronow WS, Ahn C, Kronzon I, et al. Congestive heart failure, coronary events and atherothrombotic brain infarction in elderly blacks and whites with systemic hypertension and with and without echocardiographic and electrocardiographic evidence of left ventricular hypertrophy. Am J Cardiol 1991; 67: 295-9
Aronow WS, Ahn C, Kronzon I. Comparison of incidences of congestive heart failure in older African-Americans, Hispanics and whites. Am J Cardiol 1999; 84: 611-12
Garovic VD, Bailey KR, Boerwinkle E, et al. Hypertension in pregnancy as a risk factor for cardiovascular disease later in life. J Hypertens 2010;28:826–33.
Hunter S, Robson SC. Adaptation of the maternal heart in pregnancy. Br Heart J 1992;68:540–3.
Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 2001;104:515–21.
Drenthen W, Boersma E, Balci A, et al. Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J 2010;17:2124–32.
Khairy P, Ouyang DW, Fernandes SM, et al. Pregnancy outcomes in women with congenital heart disease. Circulation 2006;113:517–24.
Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011;32:3147–97.
Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010;12:767–78.
Elkayam U, Bitar F. Valvular heart disease and pregnancy part I: native valves. J Am Coll Cardiol 2005;46:223–30.
Hameed A, Karaalp IS, Tummala PP, et al. The effect of valvular heart disease on maternal and fetal outcome of pregnancy. J Am Coll Cardiol 2001;37:893–9.
Silversides CK, Colman JM, Sermer M, et al. Cardiac risk in pregnant women with rheumatic mitral stenosis. Am J Cardiol 2003;91:1382–5.
Regitz-Zagrosek V, Lundqvist CB, Borghi C, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy; The task force on the management of cardiovascular diseases during pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011;32:3147–97.
Connolly HM. Pregnancy in women with congenital heart disease.Curr Cardiol Rep 2005;7:305–9.
Thorne S, MacGregor A, Nelson-Piercy C. Risks of contraception and pregnancy in heart disease. Heart 2006;92:1520–5.
Canobbio MM, Warnes CA, Aboulhosn J, et al. Management of pregnancy in patients with complex congenital heart disease: a scientific statement for healthcare professionals from the American Heart Association. Circulation 2017;135:e50–87.
Lindley KJ, Conner SN, Cahill AG, et al. Contraception and pregnancy planning in women with congenital heart disease. Curr Treat Options Cardiovasc Med 2015;17:50.
Clark AL, Sparrow JL, Coats AJ. Muscle fatigue and dyspnoea in chronic heart failure: two sides of the same coin? Eur Heart J 1995;16:49-52.
Hunt SA; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2005;46:e1-82.
Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 2001;104:515–21.
Drenthen W, Boersma E, Balci A, et al. Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J 2010;31:2124–32.
Silversides CK, Grewal J, Mason J, et al. Pregnancy outcomes in women with heart disease: the CARPREG II study. J Am Coll Cardiol 2018;71:2419–30.
Balci A, Sollie-Szarynska KM, van der Bijl AG, et al. Prospective validation and assessment of cardiovascular and offspring risk models for pregnant women with congenital heart disease. Heart 2014;100:1373–81.
Lindley KJ, Conner SN, Cahill AG. Adult congenital heart disease in pregnancy. Obstet Gynecol Surv 2015;70:397–407.
Langesaeter E, Dragsund M, Rosseland LA. Regional anaesthesia for a Caesarean section in women with cardiac disease: a prospective study. Acta Anaesthesiol Scand 2010;54:46–54.
Arendt KWMJ, Tsen LT. Cardiovascular alterations in the parturient undergoing cesarean delivery with neuraxial anesthesia. Exp Rev Obstet Gynecol 2014;7:59–75.
Hamlyn EL, Douglass CA, Plaat F, et al. Low-dose sequential combined spinal-epidural: an anaesthetic technique for caesarean section in patients with significant cardiac disease. Int J Obstet Anesth 2005;14:355–61.
Dresner M, Pinder A. Anaesthesia for caesarean section in women with complex cardiac disease: 34 cases using the Braun Spinocath spinal catheter. Int J Obstet Anesth 2009;18:131-6.
Abildgaard U, Sandset PM, Hammerstrom J, et al. Management of pregnant women with mechanical heart valve prosthesis: thromboprophylaxis with low molecular weight heparin. Thromb Res 2009;124:262–7.
Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 2000;160:191–6.
Ngan Kee WD, Khaw KS, Ma KC, et al. Maternal and neonatal effects of remifentanil at induction of general anesthesia for cesarean delivery: a randomized, doubleblind, controlled trial. Anesthesiology 2006;104:14–20.
Heesen M, Klohr S, Hofmann T, et al. Maternal and foetal effects of remifentanil for general anaesthesia in parturients undergoing caesarean section: a systematic review and meta-analysis. Acta Anaesthesiol Scand 2013;57:29–36.
Wadsworth R, Greer R, MacDonald JM, et al. The use of remifentanil during general anaesthesia for caesarean delivery in two patients with severe heart dysfunction. Int J Obstet Anesth 2002;11:38–43.
Manullang TR, Chun K, Egan TD. The use of remifentanil for cesarean section in a parturient with recurrent aortic coarctation. Can J Anaesth 2000;47:454–9.
Orme RM, Grange CS, Ainsworth QP, et al. General anaesthesia using remifentanil for caesarean section in parturients with critical aortic stenosis: a series of four cases. Int J Obstet Anesth 2004;13:183–7.
Goland S, Modi K, Bitar F, et al. Clinical profile and predictors of complications in peripartum cardiomyopathy. J Card Fail 2009;15:645–50.
Mhyre JM, D’Oria R, Hameed AB, et al. The maternal early warning criteria: a proposal from the national partnership for maternal safety. Obstet Gynecol 2014;124:782–6.
Tanous D, Siu SC, Mason J, et al. B-type natriuretic peptide in pregnant women with heart disease. J Am Coll Cardiol 2010;56:1247–53.
Resnik JL, Hong C, Resnik R, et al. Evaluation of B-type natriuretic peptide (BNP) levels in normal and preeclamptic women. Am J Obstet Gynecol 2005;193:450–4.